Filipa Lynce Selected Research

Filipa Lynce Research Topics

Disease

29	Breast Neoplasms (Breast Cancer) 05/2024 - 10/2014
25	Neoplasms (Cancer) 05/2024 - 01/2016
12	Triple Negative Breast Neoplasms 05/2024 - 08/2019
5	Inflammatory Breast Neoplasms 03/2024 - 01/2022
4	Neutropenia 10/2021 - 06/2018
3	Diarrhea 12/2022 - 11/2018
3	Febrile Neutropenia 10/2021 - 06/2018
2	Carcinoma (Carcinomatosis) 09/2023 - 01/2018
1	Neoplasm Metastasis (Metastasis) 03/2024
1	Lymphedema (Milroy Disease) 11/2023
1	Endometrial Neoplasms (Endometrial Cancer) 09/2023
1	Hematologic Neoplasms (Hematological Malignancy) 06/2023
1	Chronic Disease (Chronic Diseases) 12/2022
1	Pathologic Complete Response 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2021
1	Cardiotoxicity 02/2021
1	Disease Progression 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Anemia 01/2021
1	Leukopenia 01/2021
1	Nausea 11/2018
1	Fatigue 11/2018
1	Adenocarcinoma 01/2018
1	Carcinogenesis 01/2018

Drug/Important Bio-Agent (IBA)

8	Hormones (Hormone)IBA 05/2024 - 01/2017
7	human ERBB2 proteinIBA 02/2024 - 01/2017
6	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 01/2016
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 03/2024 - 01/2018
4	Capecitabine (Xeloda)FDA Link 05/2024 - 01/2021
4	olaparibIBA 04/2024 - 09/2022
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 01/2021
3	NivolumabIBA 05/2024 - 12/2023
3	Immune Checkpoint InhibitorsIBA 03/2024 - 09/2022
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 03/2024 - 01/2023
3	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2022
3	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2021
3	palbociclibIBA 06/2023 - 06/2018
3	pertuzumabIBA 12/2022 - 10/2014
2	Poly Adenosine Diphosphate RiboseIBA 03/2024 - 08/2019
2	Phenobarbital (Luminal)FDA Link 03/2024 - 11/2018
2	ruxolitinibIBA 01/2024 - 01/2021
2	Fulvestrant (Faslodex)FDA Link 06/2023 - 06/2018
2	Aromatase InhibitorsIBA 06/2023 - 11/2022
2	Estrogen ReceptorsIBA 01/2023 - 11/2018
2	Carboplatin (JM8)FDA LinkGeneric 12/2022 - 01/2021
2	Trastuzumab (Herceptin)FDA Link 12/2022 - 02/2021
2	pembrolizumabIBA 09/2022 - 08/2019
2	AnthracyclinesIBA 01/2020 - 01/2016
1	NucleotidesIBA 05/2024
1	pleiotrophin (HARP)IBA 03/2024
1	CytokinesIBA 03/2024
1	Tamoxifen FDA LinkGeneric 09/2023
1	bosutinibIBA 06/2023
1	Tyrosine Kinase InhibitorsIBA 06/2023
1	Estrogen Receptor Modulators (Antiestrogen)IBA 06/2023
1	crofelemer (SP-303)IBA 12/2022
1	Docetaxel (Taxotere)FDA Link 12/2022
1	taxaneIBA 12/2022
1	Estrogen Receptor alphaIBA 11/2022
1	LigandsIBA 11/2022
1	margetuximabIBA 01/2022
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 11/2021
1	Cyclin-Dependent Kinase 4IBA 10/2021
1	Ado-Trastuzumab EmtansineIBA 02/2021
1	sacituzumab govitecanIBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Gemcitabine FDA Link 01/2021
1	PlatinumIBA 01/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Platinum Compounds (Compounds, Platinum)IBA 01/2021
1	eribulin FDA Link 01/2021
1	OF 4647IBA 11/2020
1	Phosphotransferases (Kinase)IBA 11/2019
1	Lapatinib (GW572016)FDA Link 11/2019
1	Proteasome InhibitorsIBA 11/2019
1	Bortezomib (Velcade)FDA Link 11/2019
1	niraparibIBA 08/2019
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2018
1	Letrozole (Femara)FDA LinkGeneric 06/2018
1	Protein Tyrosine PhosphatasesIBA 01/2018
1	ParaffinIBA 01/2018
1	MAP Kinase Kinase 1IBA 01/2018
1	RANK LigandIBA 01/2018
1	Calcibiotic Root Canal SealerIBA 01/2018
1	B7-H1 AntigenIBA 01/2018

Therapy/Procedure

21	Therapeutics 03/2024 - 10/2014
13	Drug Therapy (Chemotherapy) 04/2024 - 01/2017
5	Neoadjuvant Therapy 02/2024 - 01/2022
3	Immunotherapy 01/2024 - 11/2020
2	Drug Tapering 10/2021 - 06/2018
1	Adjuvant Chemotherapy 11/2023
1	Lymph Node Excision (Lymph Node Dissection) 11/2023
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 09/2023
1	Hysterectomy 09/2023
1	Transplantation 03/2023
1	Aftercare (After-Treatment) 01/2022